TH and myeloid sarcoma: To date, Sobetirome, Sob-AM2 (85), and other recently developed Sobetirome derivatives (90–92) are the only thyromimetics reported to distribute to the CNS from systemic administration, and might represent the first class of TH agonists that can be subjected to clinical evaluation in demyelinating diseases such as MS.